[CAS NO. 138-14-7] Deferoxamine mesylate

Name: Deferoxamine mesylate
Brand: Arctom Scientific
SKU: AS538499

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [138-14-7]

Store

Catalog

AS538499

Brand

Arctom Scientific

CAS

138-14-7

DESCRIPTION [138-14-7]

Overview

MDL	MFCD00058605
Molecular Weight	656.79
Molecular Formula	C26H52N6O11S
SMILES	O=C(N(CCCCCN)O)CCC(NCCCCCN(C(CCC(NCCCCCN(C(C)=O)O)=O)=O)O)=O.CS(=O)(O)=O

For research use only. We do not sell to patients.

103 Publications Citing Use of MCE

Summary

Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 ^[1] ^[2] ^[3] ^[4] ^[5] .

In Vitro

Deferoxamine mesylate (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells ^[1] .
Deferoxamine mesylate (100 µM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels ^[2] .
Deferoxamine mesylate (5, 10, 25, 50, 100 µM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs ^[3] .
Deferoxamine mesylate (5, 10, 25, 50, 100 µM; 7 days) induces apoptosis of MSCs ^[3] .
Deferoxamine mesylate (10 µM ; 3 days) influencs the expression of adhesion proteins on MSCs ^[3] .
Deferoxamine mesylate (100 µM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis ^[1]

Cell Line:	MEFs cells
Concentration:	1 mM
Incubation Time:	16 h (hypoxia condition); 4 weeks (hyperglycemic conditions)
Result:	Significantly attenuated the hyperglycemia-associated increase in ROS levels under hypoxic high glucose conditions. Notably increased normoxic HIF transactivation in MEFs under both high glucose and normal glucose conditions.

Western Blot Analysis ^[2]

Cell Line:	HepG2 cells
Concentration:	100 µM
Incubation Time:	24 h
Result:	Showed a twofold increase of InsR mRNA levels in cells. Increased by twofold InsR binding activity at the half-maximal concentration of 1.1 nM.

Cell Proliferation Assay ^[3]

Cell Line:	TAMSCs and BMMSCs (all isolated from Male C57BL/6J mice (8 week-old; EG-7 induced tumor model))
Concentration:	5, 10, 25, 50, 100 µM
Incubation Time:	7 days (TAMSCs); 9 days (BMMSCs)
Result:	Inhibited the growth of TAMSCs and BMMSCs, and most cells are died at day 7 or 9 when exposed to 50 and 100 µM dose.

Apoptosis Analysis ^[3]

Cell Line:	TAMSCs, BMMSCs
Concentration:	5, 10, 25, 50, 100 µM
Incubation Time:	7 days
Result:	Exhibited proapoptotic effect on TAMSCs and BMMSCs cells.

Western Blot Analysis ^[3]

Cell Line:	TAMSCs, BMMSCs
Concentration:	10 µM
Incubation Time:	3 days
Result:	Remarkably decreased VCAM-1 expression in both TAMSCs and BMMSCs.

Cell Autophagy Assay ^[4]

Cell Line:	SH-SY5Y cells
Concentration:	100 µM
Incubation Time:	24 h
Result:	Increased the ratio of LC3-II/I, an indicator of autophagy, which effects were blocked when autophagy-related gene Beclin 1 was suppressed by Beclin 1 siRNA transfection. Caused a time and dose-dependent increase of HIF-1a, accompanied by the induction of autophagy.

In Vivo

Deferoxamine mesylate (560.68 mg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice ^[1] .
Deferoxamine mesylate (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Aged (21-month-old) and diabetic (12-week-old) C57BL/6J mice (excisional wound model) ^[1] .
Dosage:	560.68 mg/per (10 uL of 1 mM)
Administration:	Drip-on; once daily for 21 days.
Result:	Displayed significantly accelerated healing and increased neovascularization in both aged and diabetic mice model.

Animal Model:	Male Sprague-Dawley rats (180-200 g) ^[2] .
Dosage:	200 mg/kg
Administration:	Intraperitoneal injection; daily for 2 weeks.
Result:	Significantly increased hepatic HIF-1α protein levels, InsR protein levels, as well as Akt/PKB and activated Akt/PKB were significantly higher in the liver.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00600938	Novartis Pharmaceuticals\|Novartis	Transfusional Iron Overload\|Transfusional Hemosiderosis	November 2007	Phase 2
NCT03137966	Karolinska University Hospital	Diabetic Foot Ulcer	December 30, 2022	Phase 2
NCT01254227	Novartis Pharmaceuticals\|Novartis	Cardiac Iron Overload	January 2011	Phase 2
NCT04333550	Kermanshah University of Medical Sciences	COVID-19	April 2020	Phase 1\|Phase 2
NCT00105495	ApoPharma	Thalassemia Major\|Hemosiderosis	December 2002	Phase 4
NCT00115349	HealthCore-NERI\|National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Heart Diseases\|Beta-Thalassemia	June 2005	Phase 2
NCT04566991	Aditya S. Pandey, MD\|Michigan Medicine PKUHSC Joint Institute for Translational & Clinical Research\|University of Michigan	Aneurysmal Subarachnoid Hemorrhage	March 20, 2022	Phase 2
NCT04058197	TauTona Group	Chronic Cutaneous Ulcer\|Sickle Cell Disease	July 21, 2020	Phase 1\|Phase 2
NCT00000595	National Heart, Lung, and Blood Institute (NHLBI)	Anemia (Iron-Loading)\|Beta-Thalassemia\|Hematologic Diseases\|Hemoglobinopathies\|Thalassemia\|Iron Overload\|Hemochromatosis	January 1978	Phase 2
NCT04633889	Brigham and Women´s Hospital\|Massachusetts General Hospital\|Beth Israel Deaconess Medical Center\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Acute Kidney Injury	April 13, 2021	Phase 2
NCT05300958	Sun Yat-sen University	Triple Negative Breast Cancer	March 21, 2022	Phase 2
NCT04361032	Abderrahmane Mami Hospital\|Eshmoun Clinical Research Center\|Datametrix	COVID19\|Intensive Care Unit	September 4, 2020	Phase 3
NCT00598572	Beth Israel Deaconess Medical Center\|National Institute of Neurological Disorders and Stroke (NINDS)\|Massachusetts General Hospital\|Medical College of Wisconsin\|Medical University of South Carolina\|Hartford Hospital	Intracerebral Hemorrhage	July 2008	Phase 1
NCT05184816	Memorial Sloan Kettering Cancer Center\|Center for Experimental Therapeutics\|F.M. KIRBY FOUNDATION	Leptomeningeal Metastases	December 22, 2021	Phase 1
NCT00870883	Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude\|Conselho Nacional de Desenvolvimento Científico e Tecnológico	Hypotension\|Acute Renal Failure	March 2009	Phase 2
NCT03652467	Jinan Military General Hospital	Hepatocellular Carcinoma Non-resectable	September 1, 2018	Phase 1
NCT02367248	Capital Medical University\|Beijing Tiantan Hospital\|Peking University First Hospital\|People´s Hospital of Beijing Daxing District\|Beijing Haidian Hospital\|The 263 Hospital of PLA\|Beijing Aerospace General Hospital\|Peking University Third Hospital\|Beijing Pinggu District Hospital\|Beijing Shuyi Hospital\|General Hospital of Beijing PLA Military Region\|Beijing Luhe Hospital\|Beijing Fangshan District Liangxiang Hospital\|Beijing Neurosurgical Institute\|Beijing Jishuitan Hospital\|Beijing Ditan Hospital\|Beijing Youyi Hospital\|Xiyuan Hospital of China Academy of Chinese Medical Sciences\|Peking University People´s Hospital\|The Second Artillery General Hospital\|Chinese PLA General Hospital	Intracerebral Hemorrhage	March 2015	Phase 1\|Phase 2
NCT00777140	Germans Trias i Pujol Hospital\|Fundació Institut Germans Trias i Pujol	Ischemic Stroke, Acute	September 2008	Phase 2
NCT00658411	Dana-Farber Cancer Institute\|Brigham and Women´s Hospital	Acute Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Myelodysplastic Syndrome	August 2008	Not Applicable
NCT00061750	Novartis Pharmaceuticals\|Novartis	Beta-Thalassemia	May 2003	Phase 3
NCT00749515	Boston Children´s Hospital\|Novartis	Transfusion-dependent Hemachromatosis\|Thalassemia Major\|Sickle Cell Disease	March 2008	Phase 4
NCT00000623	HealthCore-NERI\|National Heart, Lung, and Blood Institute (NHLBI)\|Thalassemia Clinical Research Network	Anemia, Cooley´s\|Beta-Thalassemia\|Hematologic Diseases\|Thalassemia\|Osteoporosis\|Iron Overload\|Hypertension, Pulmonary	July 2000
NCT04292314	Beni-Suef University\|Maternity and Children Hospital, Makkah\|Beni-Suef Health insurance hospital\|University of Arizona	Iron Overload\|Oxidative Stress\|Thalassemia Major	November 1, 2019	Phase 2\|Phase 3
NCT00738413	Weill Medical College of Cornell University	Thalassemia	August 2008	Phase 1\|Phase 2
NCT00800761	Ospedale Microcitemico\|Azienda Sanitaria Locale di Cagliari	Iron Overload\|Cardiomyopathy	December 2001	Phase 4
NCT01459718	Novartis Pharmaceuticals\|Novartis	Transfusion-dependent β-thalassemia Patients\|Cardiac Iron Overload	January 2011	Phase 2
NCT02041299	ApoPharma\|Chiesi Canada Corp	Iron Overload\|Sickle Cell Disease\|Other Anemias	April 17, 2014	Phase 4
NCT02175225	Beth Israel Deaconess Medical Center\|Medical University of South Carolina\|National Institute of Neurological Disorders and Stroke (NINDS)\|Massachusetts General Hospital\|University of Massachusetts, Worcester\|University of Pennsylvania\|Johns Hopkins University\|Duke University\|University of North Carolina\|University of Florida\|Henry Ford Hospital\|Ohio State University\|St. Joseph´s Hospital and Medical Center, Phoenix\|University of California, San Francisco\|Oregon Health and Science University\|Yale New Haven Health System Center for Healthcare Solutions\|University of Iowa\|Hartford Hospital\|The University of Texas Health Science Center, Houston\|Rhode Island Hospital\|Stanford University\|University of Washington\|University of Calgary\|Hopital de l´Enfant-Jesus\|University of Alberta\|Rush University Medical Center\|University Hospitals Cleveland Medical Center\|Columbia University\|Weill Medical College of Cornell University\|NYU Langone Health\|Mount Sinai Hospital, New York\|Loyola University	Intracerebral Hemorrhage	October 2014	Phase 2
NCT00067080	Novartis Pharmaceuticals\|Novartis	Anemia, Sickle Cell	May 2003	Phase 2
NCT01662895	Beth Israel Deaconess Medical Center\|Medical University of South Carolina\|National Institute of Neurological Disorders and Stroke (NINDS)\|Massachusetts General Hospital\|Tufts Medical Center\|University of Massachusetts, Worcester\|University of Pennsylvania\|Johns Hopkins University\|University of Maryland\|University of Virginia\|Duke University\|University of North Carolina\|University of Florida\|The Cleveland Clinic\|Henry Ford Hospital\|Ohio State University\|St. Joseph´s Hospital and Medical Center, Phoenix\|University of California, San Francisco\|Oregon Health and Science University\|Yale New Haven Hospital\|University of Iowa\|Hartford Hospital\|The University of Texas Health Science Center, Houston\|Rhode Island Hospital\|Stanford University\|University of Washington\|University of Calgary\|Hopital de l´Enfant-Jesus\|University of Alberta\|Dalhousie University	Intracerebral Hemorrhage	March 18, 2013	Phase 2
NCT02875262	Radboud University Medical Center\|University Medical Center Groningen	Intracranial Aneurysm\|Subarachnoid Hemorrhage	December 1, 2017	Phase 1\|Phase 2
NCT00110617	Novartis Pharmaceuticals\|Novartis	Sickle Cell Disease\|Iron Overload\|Hemolytic Anemia	May 2005	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

H ₂ O : 250 mg/mL ( 380.64 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.5226 mL	7.6128 mL	15.2256 mL
5 mM	0.3045 mL	1.5226 mL	3.0451 mL
10 mM	0.1523 mL	0.7613 mL	1.5226 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: PBS

Solubility: 5.56 mg/mL (8.47 mM); Clear solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

Synonyms

Butanediamide, N⁴-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N¹-(5-aminopentyl)-N¹-hydroxy-, methanesulfonate (1:1)

Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-, monomethanesulfonate (salt)

Butanediamide, N′-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-, monomethanesulfonate (salt)

Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-, methanesulfonate

Desferrioxamine methanesulfonate

Desferrioxamine B mesylate

Desferrioxamine B methanesulfonate

Deferoxamine B mesylate

Deferrioxamine methanesulfonate

Desferrioxamine mesylate

Desferal mesylate

Desferal

Deferrioxamine B methanesulfonate

Deferoxamine mesylate

Deferoxamine methanesulfonate

DFOM

Ba 33112

NSC 644468

DFX mesylate

Desferrioxamine mesilate